Beschreibung:
<jats:sec><jats:title>Aims</jats:title><jats:p>Aim was to assess the feasibility of serum markers to identify individuals at risk for gastro-oesophageal adenocarcinoma to reduce the number of individuals requiring invasive assessment by endoscopy.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Blood samples from 56 patients with Barrett’s oesophagus and 202 non-Barrett controls who previously took part in a trial assessing the accuracy of the Cytosponge for Barrett’s oesophagus were assessed for serum pepsinogen (PG) 1 and 2, gastrin-17, trefoil factor 3 (TFF3) and <jats:italic>Helicobacter pylori</jats:italic> infection.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>PG1 was pathological (<50 ng/mL) in 26 patients (10.1%), none of whom had Barrett’s oesophagus (p<0.001). Smoking and drinking had no influence on these results. Pathological PG1 was associated with stomach pain (p=0.029), disruption of sleep (p=0.027) and disruption of diet by symptoms (p=0.019). Serum TFF3 was not associated with any clinical parameter.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Assessment of serum PG1 could be combined with a test for Barrett’s oesophagus to identify additional patients requiring endoscopy.</jats:p></jats:sec>